Can Syndecan-1 Be Used As A Biomarker In Alzheimer’s Disease?




Syndecan-1, Mild cognitive impairment, Alzheimer’s disease, Yesavage geriatric depression scale


Background: Syndecan-1 (SDC-1) is a member of the syndecan family, which includes heparan sulfate proteoglycans. SDC-1 is important for cell-cell and cell-matrix interactions. The aim of this study is to examine the relationship between serum SDC-1 levels and mild cognitive impairment (MCI) and Alzheimer’s disease (AD).

Methods: Eighty-two patients aged 65 years and over were included in the study. The Mini-Mental State Examination (MMSE) was used to evaluate the cognitive functions of the patients. Comprehensive geriatric assessment components were administered to the patients. Serum SDC-1 levels were measured with an enzyme-linked immunosorbent assay kit.

Results: When patients were grouped as control, MCI and AD, significant decreases were observed in Katz daily living activity (p<0.001), Lawton instrumental daily living activity (p=0.001), Mini-nutritional assessment (p=0.001), MMSE (p=0.001) scores. SDC-1 level was 154.88±22.85 in the control group, 157.95±19.45 in the MCI group, and 159.54±14.04 ng/mL in the AD group, and no significant correlation was observed (p=0.677). When correlation analyzes were performed with SDC-1, a negative correlation was found with the Yesavage geriatric depression scale score (Spearman rho: -0.223 p=0.044).

Conclusion: No correlation was found between SDC-1 level and AD, and it showed a negative correlation with depression. Clarifying the pathogenetic processes more clearly will guide the development of new treatment strategies.


Download data is not yet available.




How to Cite

Tuna Doğrul R, Cavusoglu C, Sengul Aycicek G, Ozsurekci C, Caliskan H, Doğan Varan H, Dikmen ZG, Halil MG, Cankurtaran M, Dogu BB. Can Syndecan-1 Be Used As A Biomarker In Alzheimer’s Disease?. Acta Medica [Internet]. 2022 Jun. 13 [cited 2024 May 30];53(2):166-72. Available from:



Original Article